Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jan 1;21(1):69-77.
doi: 10.5056/jnm14078.

Predictive factors of response to proton pump inhibitors in korean patients with gastroesophageal reflux disease

Sung Eun Kim  1 , Nayoung Kim  1 , Sooyeon Oh  2 , Hee Man Kim  3 , Moo In Park  4 , Dong Ho Lee  1 , Hyun Chae Jung  2
Affiliations

Predictive factors of response to proton pump inhibitors in korean patients with gastroesophageal reflux disease

Sung Eun Kim et al. J Neurogastroenterol Motil. .

Abstract

Background/aims: Proton pump inhibitors (PPIs) are widely used in the treatment of gastroesophageal reflux disease (GERD). However, some patients fail to respond to PPI therapy. We investigated the efficacy of response to PPI therapy in patients with GERD symptoms.

Methods: A total of 179 subjects with GERD symptoms were prospectively enrolled and diagnosed with non-erosive reflux disease (NERD, n = 100) and erosive reflux disease (n = 79) by gastroscopy and Bernstein test and/or 24-hour esophageal pH testing. Subjects then received a standard dose of daily PPI therapy for at least 4 weeks. PPI therapy response was evaluated using questionnaires including questions about demographics, GERD symptoms, GERD impact scale, Epworth sleepiness scale, Pittsburgh sleep quality index (PSQI), hospital anxiety and depression scale, and abbreviated version of the World Health Organization quality of life scale.

Results: The rates of complete (≥ 80%), satisfactory (≥ 50%), partial (< 50%), and refractory response in the 179 participants were 41.3%, 30.2%, 18.4%, and 10.1%, respectively. Thus, overall response rate (complete and satisfactory responses) was 71.5%. Multivariate analysis showed body mass index < 23 kg/m(2) (OR, 2.20; 95% CI, 1.12-4.34), higher total PSQI score (OR, 1.20; 95% CI, 1.05-1.35), history of psychotherapy or neuropsychiatric medication (OR, 2.44; 95% CI, 1.23-4.85), and NERD (OR, 3.30; 95% CI, 1.54-7.11) were associated with poor response to PPI therapy.

Conclusions: Psychological factors, sleep dysfunction, body mass index < 23 kg/m(2), and NERD seem to be the major factors that lead to a poor response to PPI treatment in patients with GERD symptoms.

Keywords: Esophagitis; Gastroesophageal reflux; Proton pump inhibitors; Psychology; Sleep disorders.

PubMed Disclaimer

Figures

Figure.
Figure.
Flow chart of study participants. GERD, gastroesophageal reflux disease; GIS, GERD impact scale; ERD, erosive reflux disease; NERD, non-erosive reflux disease.
See this image and copyright information in PMC

References

    1. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R, Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101:1900–1920. doi: 10.1111/j.1572-0241.2006.00630.x. - DOI - PubMed
    1. Lee ES, Kim N, Lee SH, et al. Comparison of risk factors and clinical responses to proton pump inhibitors in patients with erosive oesophagitis and non-erosive reflux disease. Aliment Pharmacol Ther. 2009;30:154–164. doi: 10.1111/j.1365-2036.2009.04021.x. - DOI - PubMed
    1. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108:308–328. doi: 10.1038/ajg.2012.444. - DOI - PubMed
    1. Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol. 2008;64:935–951. doi: 10.1007/s00228-008-0538-y. - DOI - PubMed
    1. El-Serag H, Becher A, Jones R. Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies. Aliment Pharmacol Ther. 2010;32:720–737. doi: 10.1111/j.1365-2036.2010.04406.x. - DOI - PubMed

LinkOut - more resources